<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92527">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053454</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTR02-005</org_study_id>
    <nct_id>NCT02053454</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Japanese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK)
      of patisiran (ALN-TTR02) in Japanese subjects
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ALN-TTR02 (serum concentrations of Transthyretin, Vitamin A, and Retinol Binding Protein)</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum concentration (Cmax) of ALN-TTR02</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of observed maximum concentration (tmax) of ALN-TTR02</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of ALN-TTR02</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of ALN-TTR02</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (CL) of ALN-TTR02</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V) of ALN-TTR02</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) of ALN-TTR02</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Transthyretin (TTR)-Mediated Amyloidosis</condition>
  <arm_group>
    <arm_group_label>patisiran (ALN-TTR02)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patisiran (ALN-TTR02)</intervention_name>
    <description>Ascending doses administered by intravenous (IV) infusion</description>
    <arm_group_label>patisiran (ALN-TTR02)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese adult males and females aged 20 to 65 years, inclusive (The subject
             was born in Japan and has lived outside of Japan for &lt;10 years, and subject's
             biological parents and grandparents are fully Japanese and were born in Japan);

          -  Subjects who are healthy as determined by clinical assessments;

          -  Females subjects must be of non-childbearing potential;

          -  Males with partners of child-bearing potential, must agree to use appropriate
             contraception.

        Exclusion Criteria:

          -  Subjects with a history of serious mental illness;

          -  Subjects who have a clinically relevant medical or surgical history;

          -  Subjects with a positive screen for alcohol or drugs of abuse;

          -  Subjects with safety laboratory test results deemed clinically significant;

          -  Subjects with known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV),
             hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection;

          -  Subjects who have received an investigational agent within the 3 months prior to
             study entry.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Gollob, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
